Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab

Graves, 2007, Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2), J Am Acad Dermatol, 56, e55, 10.1016/j.jaad.2006.07.019 Kerns, 2006, Off-label uses of biologic agents in dermatology: a 2006 update, Semin Cutan Med Surg, 25, 226, 10.1016/j.sder.2006.08.006 Jacobi, 2003, [Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders], J Dtsch Dermatol Ges, 1, 259, 10.1046/j.1610-0387.2003.02044.x Trent, 2005, Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases, Dermatol Nurs, 17, 97 Williams, 2002, Cytokine blocking agents in dermatology, Clin Exp Dermatol, 27, 585, 10.1046/j.1365-2230.2002.01149.x Scheinfeld, 2004, The medical uses and side effects of etanercept with a focus on cutaneous disease, J Drugs Dermatol, 3, 653 Alexis, 2005, Off-label dermatologic uses of anti-TNF-a therapies, J Cutan Med Surg, 9, 296, 10.1007/s10227-005-0110-7 Gamo, 2006, Biologic therapy and psoriasis, Actas Dermosifiliogr, 97, 1, 10.1016/S0001-7310(06)73342-7 Nanda, 2004, Et anercept: a clinical review of current and emerging indications, Expert Opin Pharmacother, 5, 1175, 10.1517/14656566.5.5.1175 Goffe, 2003, Etanercept: an overview, J Am Acad Dermatol, 49, S105, 10.1016/mjd.2003.554 Goffe, 2004, Etanercept (Enbrel)—an update, Skin Therapy Lett, 9, 1 Hamilton, 2004, Infectious complications of treatment with biologic agents, Curr Opin Rheumatol, 16, 393, 10.1097/01.bor.0000127594.92432.7c Olsen, 2004, New drugs for rheumatoid arthritis, N Engl J Med, 350, 2167, 10.1056/NEJMra032906 Swale, 2003, Etanercept-induced systemic lupus erythematosus, Clin Exp Dermatol, 28, 604, 10.1046/j.1365-2230.2003.01411.x Shakoor, 2002, Druginduced systemic lupus erythematosus associated with etanercept therapy, Lancet, 359, 579, 10.1016/S0140-6736(02)07714-0 Richez, 2005, Lupus erythematosus manifestations exacerbated by etanercept therapy in a patient with mixed connective tissue disease, Clin Exp Rheumatol, 23, 273 Mor, 2005, Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept, J Rheumatol, 32, 740 Lepore, 2003, Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis, Clin Exp Rheumatol, 21, 276 Kang, 2006, Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis, J Korean Med Sci, 21, 946, 10.3346/jkms.2006.21.5.946 Debandt, 2003, Anti-TNF-alpha-induced systemic lupus syndrome, Clin Rheumatol, 22, 56, 10.1007/s10067-002-0654-5 De Bandt, 2005, Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey, Arthritis Res Ther, 7, R545, 10.1186/ar1715 Carlson, 2003, Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis, Arthritis Rheum, 48, 1165, 10.1002/art.11033 Cairns, 2002, New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis, Ann Rheum Dis, 61, 1031, 10.1136/ard.61.11.1031 Bleumink, 2001, Etanercept-induced subacute cutaneous lupus erythematosus, Rheumatology (Oxford), 40, 1317, 10.1093/rheumatology/40.11.1317 Benucci, 2005, Drug-induced lupus after treatment with infliximab in rheumatoid arthritis, J Clin Rheumatol, 11, 47, 10.1097/01.rhu.0000152148.55133.ba Norman, 2006, Case reports of etanercept in inflammatory dermatoses, J Am Acad Dermatol, 54, S139, 10.1016/j.jaad.2005.11.1090 Fautrel, 2002, Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al, Arthritis Rheum, 46, 1408, 10.1002/art.10271 Hall, 2006, Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor, Arthritis Rheum, 55, 982, 10.1002/art.22358 Efthimiou, 2006, Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients, Ann Rheum Dis, 65, 1233, 10.1136/ard.2005.048744 Iannone, 2006, Use of etanercept in the treatment of dermatomyositis: a case series, J Rheumatol, 33, 1802 Ellman, 2000, Etanercept as treatment for diffuse scleroderma: a pilot study, Arthritis Rheum, 43, 392 Yamauchi, 2006, Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept, J Am Acad Dermatol, 54, S122, 10.1016/j.jaad.2005.11.1089 Hubbard, 2005, Systemic pyoderma gangrenosum responding to infliximab and adalimumab, Br J Dermatol, 152, 1059, 10.1111/j.1365-2133.2005.06467.x Roy, 2006, The treatment of pyoderma gangrenosum using etanercept, J Am Acad Dermatol, 54, S128, 10.1016/j.jaad.2005.10.058 McGowan, 2004, Treatment of pyoderma gangrenosum with etanercept, J Drugs Dermatol, 3, 441 Goldenberg, 2005, Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis, J Dermatolog Treat, 16, 347, 10.1080/09546630500424722 Pastor, 2006, Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept), Clin Exp Dermatol, 31, 152, 10.1111/j.1365-2230.2005.01972.x Disla, 2004, Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis, J Clin Rheumatol, 10, 50, 10.1097/01.rhu.0000111315.94725.9c Holler, 1990, Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation, Blood, 75, 1011, 10.1182/blood.V75.4.1011.1011 Holler, 1993, Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation, Transplant Proc, 25, 1234 Holler, 1998, Cytokines in GvH and GvL, Bone Marrow Transplant, 22, S3 Schmaltz, 2003, Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation, Blood, 101, 2440, 10.1182/blood-2002-07-2109 Jacobsohn, 2004, Anti-cytokine therapy for the treatment of graft-versus-host disease, Curr Pharm Des, 10, 1195, 10.2174/1381612043452569 Andolina, 2000, Etanercept in graft-versus-host disease, Bone Marrow Transplant, 26, 929, 10.1038/sj.bmt.1702638 Wolff, 2005, Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept, Bone Marrow Transplant, 35, 1003, 10.1038/sj.bmt.1704929 Kennedy, 2006, Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/− mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease, Bone Marrow Transplant, 37, 1143, 10.1038/sj.bmt.1705380 Uberti, 2005, Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease, Biol Blood Marrow Transplant, 11, 680, 10.1016/j.bbmt.2005.05.009 Busca, 2007, Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation, Am J Hematol, 82, 45, 10.1002/ajh.20752 Chiang, 2002, Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease, Transplantation, 73, 665, 10.1097/00007890-200202270-00035 Ogden, 2006, Recalcitrant hand pompholyx: variable response to etanercept, Clin Exp Dermatol, 31, 145, 10.1111/j.1365-2230.2005.01947.x Buka, 2005, Etanercept is minimally effective in 2 children with atopic dermatitis, J Am Acad Dermatol, 53, 358, 10.1016/j.jaad.2005.03.013 Yamauchi, 2006, Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept, J Am Acad Dermatol, 54, S121, 10.1016/j.jaad.2005.10.055 Sacher, 2002, Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept, J Am Acad Dermatol, 46, 113, 10.1067/mjd.2001.119100 Prey, 2007, Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept, Acta Derm Venereol, 87, 74, 10.2340/00015555-0132 Canizares, 2006, Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients, Arch Dermatol, 142, 1457, 10.1001/archderm.142.11.1457 Lin, 2005, Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser, Arch Dermatol, 141, 680, 10.1001/archderm.141.6.680 Berookhim, 2004, Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept, Cutis, 74, 245 Gubinelli, 2006, Pemphigus foliaceus treated with etanercept, J Am Acad Dermatol, 55, 1107, 10.1016/j.jaad.2006.08.041 Utz, 2003, Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis, Chest, 124, 177, 10.1378/chest.124.1.177 Baughman, 2005, Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial, Chest, 128, 1062, 10.1016/S0012-3692(15)50471-6 Khanna, 2003, Etanercept ameliorates sarcoidosis arthritis and skin disease, J Rheumatol, 30, 1864 Tuchinda, 2006, Etanercept for chronic progressive cutaneous sarcoidosis, J Drugs Dermatol, 5, 538 González-López, 2006, Development of sarcoidosis during etanercept therapy, Arthritis Rheum, 55, 817, 10.1002/art.22238 Kudrin, 2007, Sarcoid-like granulomatous disease following etanercept treatment for RA, J Rheumatol, 34, 648 Verschueren, 2007, Development of sarcoidosis in etanercepttreated rheumatoid arthritis patients, Clin Rheumatol, 26, 1969, 10.1007/s10067-007-0594-1 Shupack, 2006, Resolving granuloma annulare with etanercept, Arch Dermatol, 142, 394 Kreuter, 2006, Failure of etanercept therapy in disseminated granuloma annulare, Arch Dermatol, 142, 1236, 10.1001/archderm.142.9.1236 Cummins, 2004, Generalized necrobiosis lipoidica treated with a combination of split-thickness autografting and immunomodulatory therapy, Int J Dermatol, 43, 852, 10.1111/j.1365-4632.2004.02120.x Zeichner, 2006, Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept, J Am Acad Dermatol, 54, S120, 10.1016/j.jaad.2005.11.1042 Pasternack, 2005, Silicone granulomas treated with etanercept, Arch Dermatol, 141, 13, 10.1001/archderm.141.1.13 Desai, 2006, Etanercept therapy for silicone granuloma, J Drugs Dermatol, 5, 894 Rapaport, 2005, Silicone granulomas treated with etanercept, Arch Dermatol, 141, 1171, 10.1001/archderm.141.9.1171-a Lin, 2006, Etanercept treatment of cutaneous granulomas in common variable immunodeficiency, J Allergy Clin Immunol, 117, 878, 10.1016/j.jaci.2006.01.034 Melikoglu, 2005, Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study, J Rheumatol, 32, 98 Sommer, 2005, A case of mucocutaneous Behcet's disease responding to etanercept, J Am Acad Dermatol, 52, 717, 10.1016/j.jaad.2004.11.031 Atzeni, 2005, Successful treatment of resistant Behcet's disease with etanercept, Clin Exp Rheumatol, 23, 729 Estrach, 2002, Behcet's syndrome: response to infliximab after failure of etanercept, Rheumatology (Oxford), 41, 1213, 10.1093/rheumatology/41.10.1213-c Stone, 2001, Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety, Arthritis Rheum, 44, 1149, 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F Wegener's granulomatosis Etanercept Trial (WGET) Research Group, 2005, Etanercept plus standard therapy for Wegener's granulomatosis, N Engl J Med, 352, 351, 10.1056/NEJMoa041884 Kleinert, 2004, [Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade], Wien Klin Wochenschr, 116, 334, 10.1007/BF03040906 Feinstein, 2005, Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade, J Clin Rheumatol, 11, 219, 10.1097/01.rhu.0000173225.41933.83 Kovach, 2004, Treatment of multicentric reticulohistiocytosis with etanercept, Arch Dermatol, 140, 919, 10.1001/archderm.140.8.919 Lovelace, 2005, Etanercept and the treatment of multicentric reticulohistiocytosis, Arch Dermatol, 141, 1167, 10.1001/archderm.141.9.1167-b Matejicka, 2003, Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al, Arthritis Rheum, 48, 864, 10.1002/art.10781 Chave, 2005, Toxic epidermal necrolysis: current evidence, practical management and future directions, Br J Dermatol, 153, 241, 10.1111/j.1365-2133.2005.06721.x Famularo, 2007, Etanercept for toxic epidermal necrolysis, Ann Pharmacother, 41, 1083, 10.1345/aph.1K001 Campione, 2006, Severe acne successfully treated with etanercept, Acta Derm Venereol, 86, 256, 10.2340/00015555-0046 Cortis, 2004, Abnormal production of tumor necrosis factor (TNF)—alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected], J Pediatr, 145, 851, 10.1016/j.jpeds.2004.08.001 Cusack, 2006, Etanercept: effective in the management of hidradenitis suppurativa, Br J Dermatol, 154, 726, 10.1111/j.1365-2133.2005.07067.x Henderson, 2006, Case reports: treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor-Fc fusion protein etanercept, J Drugs Dermatol, 5, 1010 Robinson, 2003, Recalcitrant, recurrent aphthous stomatitis treated with etanercept, Arch Dermatol, 139, 1259, 10.1001/archderm.139.10.1259 Strober, 2005, Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study, J Am Acad Dermatol, 52, 1082, 10.1016/j.jaad.2005.03.039 Abramovits, 2006, Failure of two TNF-alpha blockers to influence the course of alopecia areata, Skinmed, 5, 177, 10.1111/j.1540-9740.2006.05443.x Posten, 2005, Recurrence of alopecia areata in a patient receiving etanercept injections, Arch Dermatol, 141, 759, 10.1001/archderm.141.6.759 Minni, 2006, A novel therapeutic approach to erythema annulare centrifugum, J Am Acad Dermatol, 54, S134, 10.1016/j.jaad.2005.11.1044 Hussein, 2003, Etanercept therapy in patients with advanced primary amyloidosis, Med Oncol, 20, 283, 10.1385/MO:20:3:283 Querfeld, 2004, Successful treatment of recalcitrant, erythroderma-associated pruritus with etanercept, Arch Dermatol, 140, 1539, 10.1001/archderm.140.12.1539 Tsimberidou, 2004, Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas, J Am Acad Dermatol, 51, 200, 10.1016/j.jaad.2003.05.009 Bogle, 2006, Successful treatment of a widespread inflammatory verrucous epidermal nevus with etanercept, Arch Dermatol, 142, 401, 10.1001/archderm.142.3.401 Wagner, 2002, Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome, Arthritis Rheum, 46, 1965, 10.1002/art.10539 van Noesel, 1988, Regulatory properties of LFA-1 alpha and beta chains in human T-lymphocyte activation, Nature, 333, 850, 10.1038/333850a0 Shear, 2006, Efalizumab, a reversible T-cell modulator for psoriasis, J Cutan Med Surg, 9, 4 http://emea.europa.eu/humandocs/Humans/EPAR/rap-tiva/ raptiva.htm. Consultado 30 junio 2007. Langley, 2005, Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience, Clin Ther, 27, 1317, 10.1016/j.clinthera.2005.09.007 Goffe, 2004, Disseminated granuloma annulare resolved with the T-cell modulator efalizumab, Arch Dermatol, 140, 1287, 10.1001/archderm.140.10.1287 Cheng, 2006, Oral erosive lichen planus treated with efalizumab, Arch Dermatol, 142, 680, 10.1001/archderm.142.6.680 Heffernan, 2007, A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planus, J Drugs Dermatol, 6, 310 Bohm, 2007, Lichen planus responding to efalizumab, J Am Acad Dermatol, 56, S92, 10.1016/j.jaad.2006.10.957 Weinberg, 2006, Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab, Arch Dermatol, 14, 555, 10.1001/archderm.142.5.555 Hassan, 2007, Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab, J Am Acad Dermatol, 56, 217, 10.1016/j.jaad.2006.08.025 Takiguchi, 2007, Efalizumab for severe atopic dermatitis: a pilot study in adults, J Am Acad Dermatol, 56, 222, 10.1016/j.jaad.2006.08.031 Huber, 2006, Treatment of recalcitrant dermatomyositis with efalizumab, Acta Derm Venereol, 86, 254, 10.2340/00015555-0058 Dedrick, 2002, Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody, Transpl Immunol, 9, 181, 10.1016/S0966-3274(02)00029-1 McMichael, 2003, The new biologics in psoriasis: possible treatments for alopecia areata, J Investig Dermatol Symp Proc, 8, 217, 10.1046/j.1087-0024.2003.00813.x Kaelin, 2006, Treatment of alopecia areata partim universalis with efalizumab, J Am Acad Dermatol, 55, 529, 10.1016/j.jaad.2006.05.062 Tosti, 2006, Alopecia areata during treatment with biologic agents, Arch Dermatol, 142, 1653, 10.1001/archderm.142.12.1653 Clayton, 2006, Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab, J Am Acad Dermatol, 54, 892, 10.1016/j.jaad.2005.08.025 Bentley, 2006, Efalizumab-induced subacute cutaneous lupus erythematosus, J Am Acad Dermatol, 54, S242, 10.1016/j.jaad.2005.10.037 Usmani, 2007, Efalizumab in the treatment of discoid lupus erythematosus, Arch Dermatol, 143, 873, 10.1001/archderm.143.7.873 http://www.fda.gov/cder/biologics/products/alef-bio013003.htm. Consultado 30 junio 2007. Hodak, 2004, Alefacept: a review of the literature and practical guidelines for management, Dermatol Ther, 17, 383, 10.1111/j.1396-0296.2004.04041.x Fivenson, 2006, Treatment of generalized lichen planus with alefacept, Arch Dermatol, 142, 151, 10.1001/archderm.142.2.151 Heffernan, 2005, Alefacept for alopecia areata, Arch Dermatol, 141, 1513, 10.1001/archderm.141.12.1513 García-Zuazaga, 2006, Cutaneous sarcoidosis successfully treated with alefacept, J Cutan Med Surg, 10, 300, 10.2310/7750.2006.00063 Chi, 2005, Scleroderma and failed response to alefacept, Rheumatology (Oxford), 44, 1328, 10.1093/rheumatology/kei017 Shapira, 2005, Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report, Bone Marrow Transplant, 36, 1097, 10.1038/sj.bmt.1705185 Grillo-López, 1999, Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma, Semin Oncol, 26, 66 Maloney, 1997, IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma, J Clin Oncol, 15, 3266, 10.1200/JCO.1997.15.10.3266 Maloney, 1997, IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, Blood, 90, 2188, 10.1182/blood.V90.6.2188 Golay, 2000, Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis, Blood, 95, 3900, 10.1182/blood.V95.12.3900 Foran, 2000, European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma, J Clin Oncol, 18, 317, 10.1200/JCO.2000.18.2.317 Schulz, 2007, Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis, J Natl Cancer Inst, 99, 706, 10.1093/jnci/djk152 Mohrbacher, 2005, B cell non-Hodgkin's lymphoma: rituximab safety experience, Arthritis Res Ther, 7, S19, 10.1186/ar1739 Pérez-Gala, 2006, Cytokine-release syndrome related to rituximab limited to lesions and excision scars of lesions of primary cutaneous lymphoma, Arch Dermatol, 142, 1516, 10.1001/archderm.142.11.1516 Heinzerling, 2000, Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma, Cancer, 89, 1835, 10.1002/1097-0142(20001015)89:8<1835::AID-CNCR26>3.0.CO;2-H Emery, 2006, The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial, Arthritis Rheum, 54, 1390, 10.1002/art.21778 Looney, 2004, B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab, Arthritis Rheum, 50, 2580, 10.1002/art.20430 Cambridge, 2006, B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles, Arthritis Rheum, 54, 3612, 10.1002/art.22211 Looney, 2004, B cells as therapeutic targets for rheumatic diseases, Curr Opin Rheumatol, 16, 180, 10.1097/00002281-200405000-00003 Looney, 2005, B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis, Rheumatology (Oxford), 44, ii13, 10.1093/rheumatology/keh618 Looney, 2005, B cell-targeted therapy in diseases other than rheumatoid arthritis, J Rheumatol Suppl, 73, 25 Looney, 2005, Treatment of SLE with anti-CD20 monoclonal antibody, Curr Dir Autoimmun, 8, 193, 10.1159/000082104 Tahir, 2005, Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab, Rheumatology (Oxford), 44, 561, 10.1093/rheumatology/keh533 Lehembre, 2006, Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus, Ann Dermatol Venereol, 133, 53, 10.1016/S0151-9638(06)70845-6 Tanaka, 2007, A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus, Mod Rheumatol, 17, 191, 10.3109/s10165-007-0565-z Sabugo, 2005, Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: report of one case, Rev Med Chil, 133, 681, 10.4067/S0034-98872005000600010 Saito, 2005, Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus, Rheumatology (Oxford), 44, 1462, 10.1093/rheumatology/kei075 Van den Bergh, 2005, Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature, Acta Clin Belg, 60, 102, 10.1179/acb.2005.019 Kneitz, 2002, Effective B cell depletion with rituximab in the treatment of autoimmune diseases, Immunobiology, 206, 519, 10.1078/0171-2985-00200 Tokunaga, 2005, Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab, Rheumatology (Oxford), 44, 176, 10.1093/rheumatology/keh443 Saigal, 2003, Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab, J Am Acad Dermatol, 49, S283, 10.1016/S0190-9622(03)00744-8 Greenberg, 2004, Uncertainties in the pathogenesis of adult dermatomyositis, Curr Opin Neurol, 17, 359, 10.1097/00019052-200406000-00018 Levine, 2005, Rituximab in the treatment of dermatomyositis: an open-label pilot study, Arthritis Rheum, 52, 601, 10.1002/art.20849 Chung, 2007, A pilot trial of rituximab in the treatment of patients with dermatomyositis, Arch Dermatol, 143, 763, 10.1001/archderm.143.6.763 Dinh, 2007, Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases, J Am Acad Dermatol, 56, 148, 10.1016/j.jaad.2006.05.068 Noss, 2006, Rituximab as therapy for refractory polymyositis and dermatomyositis, J Rheumatol, 33, 1021 Chiappetta, 2005, Rituximab in the treatment of refractory dermatomyositis, J Clin Rheumatol, 11, 264, 10.1097/01.rhu.0000182155.08982.60 Keogh, 2005, Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis, Arthritis Rheum, 52, 262, 10.1002/art.20718 Eriksson, 2005, Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab, J Intern Med, 257, 540, 10.1111/j.1365-2796.2005.01494.x Ferraro, 2005, Effective therapeutic use of rituximab in refractory Wegener's granulomatosis, Nephrol Dial Transplant, 20, 622, 10.1093/ndt/gfh599 Specks, 2001, Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy, Arthritis Rheum, 44, 2836, 10.1002/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W Memet, 2005, Wegener granulomatosis with massive intracerebral hemorrhage: remission of disease in response to rituximab, J Clin Rheumatol, 11, 314, 10.1097/01.rhu.0000191217.11688.3c Cheung, 2005, Successful treatment of Wegener's granulomatosis associated scleritis with rituximab, Br J Ophthalmol, 89, 1542, 10.1136/bjo.2005.075689 Omdal, 2005, Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response, Scand J Rheumatol, 34, 229, 10.1080/02813430510015269 Bachmeyer, 2005, Rituximab is an alternative in a case of contra-indication of cyclophosphamide in Wegener's granulomatosis, Nephrol Dial Transplant, 20, 1274, 10.1093/ndt/gfh852 Tamura, 2007, Two cases of refractory Wegener's granulomatosis successfully treated with rituximab, Intern Med, 46, 409, 10.2169/internalmedicine.46.6156 Kallenbach, 2005, Rituximab induced remission in a patient with Wegener's granulomatosis, Nephron Clin Pract, 99, 92, 10.1159/000083426 Tektonidou, 2006, Sustained 3-year remission after rituximab treatment in a patient with refractory Wegener's granulomatosis, Clin Exp Rheumatol, 24, S103 Stasi, 2006, Long-term observation of patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with rituximab, Rheumatology (Oxford), 45, 1432, 10.1093/rheumatology/kel098 Henes, 2007, Rituximab for treatment-resistant extensive Wegener;s granulomatosis-additive effects of a maintenance treatment with leflunomide, Clin Rheumatol, 26, 1711, 10.1007/s10067-007-0643-9 Keogh, 2006, Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial, Am J Respir Crit Care Med, 173, 180, 10.1164/rccm.200507-1144OC Aries, 2006, Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations, Ann Rheum Dis, 65, 853, 10.1136/ard.2005.044420 Aries, 2006, Rituximab in refractory Wegener's granulomatosis: Favorable or not?, Am J Respir Crit Care Med, 173, 815, 10.1164/ajrccm.173.7.815a Brihaye, 2007, Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients, Clin Exp Rheumatol, 25, S23 Chu, 2007, Severe, refractory, nonmalignant type I cryoglobulinemia treated with alemtuzumab, Rheumatol Int, 27, 1173, 10.1007/s00296-007-0354-1 Nehme-Schuster, 2005, Rituximab inefficiency during type I cryoglobulinaemia, Rheumatology (Oxford), 44, 410, 10.1093/rheumatology/keh503 Mantha, 2005, Unusual leukemia presentations. Case 3. Type I IgGlambda cryoglobulinemia associated with chronic lymphocytic leukemia, J Clin Oncol, 23, 5841, 10.1200/JCO.2005.07.004 Sansonno, 2003, Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20, Blood, 101, 3818, 10.1182/blood-2002-10-3162 Zaja, 2003, Efficacy and safety of rituximab in type II mixed cryoglobulinemia, Blood, 101, 3827, 10.1182/blood-2002-09-2856 Zaja, 2002, Rituximab for the treatment of type II mixed cryoglobulinemia, Arthritis Rheum, 46, 2252, 10.1002/art.10345 Zaja, 1999, Rituximab for the treatment of type II mixed cryoglobulinemia, Haematologica, 84, 1157 Arzoo, 2002, Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab), Ann Rheum Dis, 61, 922, 10.1136/ard.61.10.922 Cai, 2006, Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab, J Rheumatol, 33, 1197 Ghijsels, 2004, Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure, Am J Kidney Dis, 43, e34, 10.1053/j.ajkd.2003.12.057 Koukoulaki, 2005, Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab, Nephrol Dial Transplant, 20, 213, 10.1093/ndt/gfh564 Lamprecht, 2003, Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis, Ann Rheum Dis, 62, 1230, 10.1136/ard.2002.004929 Cohen, 2007, Lack of efficacy of rituximab in a patient with essential mixed cryoglobulinaemia, Rheumatology (Oxford), 46, 366, 10.1093/rheumatology/kel387 Salopek, 2002, Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder, J Am Acad Dermatol, 47, 785, 10.1067/mjd.2002.126273 Virgolini, 2003, Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory Pemphigus vulgaris: report of a case, Haematologica, 88, 24 Cooper, 2003, Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab), Clin Exp Dermatol, 28, 366, 10.1046/j.1365-2230.2003.01283.x Herrmann, 2003, Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab), Br J Dermatol, 148, 602, 10.1046/j.1365-2133.2003.05209_10.x Morrison, 2004, Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab), J Am Acad Dermatol, 51, 817, 10.1016/j.jaad.2004.06.007 Espana, 2004, Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations, J Am Acad Dermatol, 50, 974, 10.1016/j.jaad.2003.08.021 Dupuy, 2004, Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody), Arch Dermatol, 140, 91, 10.1001/archderm.140.1.91 Cecchi, 2005, Severe pemphigus vulgaris treated with rituximab (Mabthera), J Dermatol, 32, 862, 10.1111/j.1346-8138.2005.tb00862.x Kong, 2005, Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab), Pediatr Dermatol, 22, 461, 10.1111/j.1525-1470.2005.00118.x Arin, 2005, Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus, Br J Dermatol, 153, 620, 10.1111/j.1365-2133.2005.06651.x Schmidt, 2005, Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab, Br J Dermatol, 153, 449, 10.1111/j.1365-2133.2005.06740.x Wenzel, 2005, Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants, Acta Derm Venereol, 85, 185 Ahmed, 2006, Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin, N Engl J Med, 355, 1772, 10.1056/NEJMoa062930 Domínguez-Fernández, 2006, [Pemphigus vulgaris treated with rituximab], Actas Dermosifiliogr, 97, 221, 10.1016/S0001-7310(06)73387-7 Niedermeier, 2006, Delayed response of oral pemphigus vulgaris to rituximab treatment, Eur J Dermatol, 16, 266 Esposito, 2006, Long-lasting remission of pemphigus vulgaris treated with rituximab, Acta Derm Venereol, 86, 87, 10.2340/00015555-0007 Pitarch, 2006, [Treatment of severe refractory pemphigus vulgaris with rituximab], Actas Dermosifiliogr, 97, 48, 10.1016/S0001-7310(06)73348-8 Belgi, 2006, Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed, Clin Exp Dermatol, 31, 143, 10.1111/j.1365-2230.2005.01941.x Antonucci, 2007, Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): Five cases, J Dermatolog Treat, 18, 178, 10.1080/09546630701286110 Marzano, 2007, Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab), Dermatology, 214, 310, 10.1159/000099591 Goh, 2007, Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients, Br J Dermatol, 156, 990, 10.1111/j.1365-2133.2007.07800.x Borel, 2007, [Rituximab induced remission of pemphigus vulgaris: 2 cases], Rev Med Interne, 28, 266, 10.1016/j.revmed.2006.11.012 Schmidt, 2007, Rituximab in autoimmune bullous diseases: mixed responses and adverse effects, Br J Dermatol, 156, 352, 10.1111/j.1365-2133.2006.07646.x Heizmann, 2001, Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL, Am J Hematol, 66, 142, 10.1002/1096-8652(200102)66:2<142::AID-AJH1032>3.0.CO;2-0 Borradori, 2001, Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus, Arch Dermatol, 137, 269 Gergely, 2003, Successful treatment of B cell chronic lymphocytic leukemiaassociated severe paraneoplastic pemphigus with cyclosporin A, Acta Haematol, 109, 202, 10.1159/000070972 Rossum, 2004, Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities, Leuk Lymphoma, 45, 2327, 10.1080/10428190410001733781 Imataki, 2006, [A case of follicular lymphoma complicated with lethal pemphigus], Gan To Kagaku Ryoho, 33, 1677 Barnadas, 2006, Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature, J Eur Acad Dermatol Venereol, 20, 69, 10.1111/j.1468-3083.2005.01345.x Hoque, 2007, Paraneoplastic pemphigus associated with CD20-positive follicular non-Hodgkin's lymphoma treated with rituximab: a third case resistant to rituximab therapy, Clin Exp Dermatol, 32, 172, 10.1111/j.1365-2230.2006.02331.x Taintor, 2007, A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukaemia, J Am Acad Dermatol, 56, S73, 10.1016/j.jaad.2006.11.023 Goebeler, 2003, Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab, Br J Dermatol, 149, 899, 10.1046/j.1365-2133.2003.05580.x Connelly, 2007, Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment, Pediatr Dermatol, 24, 172, 10.1111/j.1525-1470.2007.00369.x McGinness, 2006, Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) associated with pemphigoid nodularis: a case report and review of the literature, J Am Acad Dermatol, 55, 143, 10.1016/j.jaad.2005.08.047 Crichlow, 2007, A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita, Br J Dermatol, 156, 194, 10.1111/j.1365-2133.2006.07596.x Niedermeier, 2007, Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies), Arch Dermatol, 143, 192, 10.1001/archderm.143.2.192 Schmidt, 2006, Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab, Arch Dermatol, 142, 147, 10.1001/archderm.142.2.147 Bhol, 1995, Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity, Proc Natl Acad Sci U S A, 92, 5239, 10.1073/pnas.92.11.5239 Schadlow, 2003, Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus, J Drugs Dermatol, 2, 564 Ratanatharathorn, 2003, Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody, Biol Blood Marrow Transplant, 9, 505, 10.1016/S1083-8791(03)00216-7 Rouquette-Gally, 1988, Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients, Transplantation, 46, 238, 10.1097/00007890-198808000-00010 Saito, 2002, CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse, J Clin Invest, 109, 1453, 10.1172/JCI0215078 Canninga-van Dijk, 2004, Anti-CD20 monoclonal antibody treatment in 6 patients with therapyrefractory chronic graft-versus-host disease, Blood, 104, 2603, 10.1182/blood-2004-05-1855 Okamoto, 2006, Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease, Leukemia, 20, 172, 10.1038/sj.leu.2403996 Cutler, 2006, Rituximab for steroid-refractory chronic graft-versus-host disease, Blood, 108, 756, 10.1182/blood-2006-01-0233 Zaja, 2007, Treatment of refractory chronic GVHD with Rituximab: a GITMO study, Bone Marrow Transplant, 40, 273, 10.1038/sj.bmt.1705725 Kamble, 2006, Rituximab responsive refractory acute graft-versus-host disease, Biol Blood Marrow Transplant, 12, 1201, 10.1016/j.bbmt.2006.06.013 Ratanatharathorn, 2000, Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease, Ann Intern Med, 133, 275, 10.7326/0003-4819-133-4-200008150-00011 Szabolcs, 2002, Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease, Bone Marrow Transplant, 30, 327, 10.1038/sj.bmt.1703654 Carella, 2007, Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease, Leuk Lymphoma, 48, 623, 10.1080/10428190601094362 Milgrom, 1999, Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group, N Engl J Med, 341, 1966, 10.1056/NEJM199912233412603 http://emea.europa.eu/humandocs/Humans/EPAR/xolair/xolair.htm. Consultado 30 junio 2007. Leynadier, 2004, Effect of omalizumab in health care workers with occupational latex allergy, J Allergy Clin Immunol, 113, 360, 10.1016/j.jaci.2003.11.020 Casale, 2001, Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial, Jama, 286, 2956, 10.1001/jama.286.23.2956 Kaliner, 2004, Omalizumab and the treatment of allergic rhinitis, Curr Allergy Asthma Rep, 4, 237, 10.1007/s11882-004-0032-2 Okubo, 2006, Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis, Allergol Int, 55, 379, 10.2332/allergolint.55.379 Deniz, 2005, Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody, Clin Rev Allergy Immunol, 29, 31, 10.1385/CRIAI:29:1:031 Dreyfus, 2006, Characterization of an anaphylactoid reaction to omalizumab, Ann Allergy Asthma Immunol, 96, 624, 10.1016/S1081-1206(10)63560-0 Lanier, 2005, Unanswered questions and warnings involving anti-immunoglobulin E therapy based on 2-year observation of clinical experience, Allergy Asthma Proc, 26, 435 Scheinfeld, 2005, Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody, Dermatol Online J, 11, 2 Soler, 2001, The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics, Eur Respir J, 18, 254, 10.1183/09031936.01.00092101 http://emea.europa.eu/humandocs/PDFs/EPAR/Xolair/H-606-PI-es.pdf. Consultado 30 junio 2007. Schmitt, 2007, Omalizumab as a therapeutic option in atopic eczema. Current evidence and potential benefit, Hautarzt, 58, 130 Johansson, 2002, Omalizumab and the immune system: an overview of preclinical and clinical data, Ann Allergy Asthma Immunol, 89, 132, 10.1016/S1081-1206(10)61928-X Simpson, 2005, Atopic dermatitis, J Am Acad Dermatol, 53, 115, 10.1016/j.jaad.2005.01.130 Beck, 2006, Wanted: A study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis, J Am Acad Dermatol, 55, 540, 10.1016/j.jaad.2006.01.037 Krathen, 2005, Failure of omalizumab for treatment of severe adult atopic dermatitis, J Am Acad Dermatol, 53, 338, 10.1016/j.jaad.2005.02.014 Lane, 2006, Treatment of recalcitrant atopic dermatitis with omalizumab, J Am Acad Dermatol, 54, 68, 10.1016/j.jaad.2005.09.030 Vigo, 2006, Efficacy of anti-IgE therapy in patients with atopic dermatitis, J Am Acad Dermatol, 55, 168, 10.1016/j.jaad.2005.12.045 Carter, 2007, Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis, J Allergy Clin Immunol, 119, 1550, 10.1016/j.jaci.2007.03.032 Mankad, 2005, Omalizumab: other indications and unanswered questions, Clin Rev Allergy Immunol, 29, 17, 10.1385/CRIAI:29:1:017 http://emea.europa.eu/humandocs/PDFs/EPAR/Zena-pax/H-198-PI-es.pdf. Consultado 30 junio 2007. Mockenhaupt, 2005, Daclizumab: a novel therapeutic option in severe bullous pemphigoid, Acta Derm Venereol, 85, 65, 10.1080/00015550410022221 Renkl, 2004, A novel therapeutic option in pemphigus vulgaris: humanized monoclonal anti-CD25 antibody, Br J Dermatol, 150, 1220, 10.1111/j.1365-2133.2004.05977.x Egan, 2001, Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab, Clin Immunol, 101, 146, 10.1006/clim.2001.5113 Osborne, 2006, Novel treatment of Sezary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor alpha antibody), Br J Dermatol, 155, 617, 10.1111/j.1365-2133.2006.07355.x Krueger, 2000, Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis, J Am Acad Dermatol, 43, 448, 10.1067/mjd.2000.106515 Wohlrab, 2001, Treatment of recalcitrant psoriasis with daclizumab, Br J Dermatol, 144, 209, 10.1046/j.1365-2133.2001.03991.x Dichmann, 2002, Humanized monoclonal anti-CD25 antibody as a novel therapeutic option in HIV-associated psoriatic erythroderma, J Am Acad Dermatol, 47, 635, 10.1067/mjd.2002.122751 http://emea.europa.eu/humandocs/PDFs/EPAR/Simu-lect/H-207-PI-es.pdf. Consultado 30 junio 2007. Haufs, 2001, Epidermolysis bullosa acquisita treated with basiliximab, an interleukin-2 receptor antibody, Acta Derm Venereol, 81, 72, 10.1080/000155501750208353 Bagel, 1998, Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial, J Am Acad Dermatol, 38, 938, 10.1016/S0190-9622(98)70590-0 Owen, 2000, Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody, Clin Exp Dermatol, 25, 195, 10.1046/j.1365-2230.2000.00612.x Bell, 2002, Use of basiliximab as a cyclosporinsparing agent in palmoplantar pustular psoriasis with myalgia as an adverse effect, Br J Dermatol, 147, 606, 10.1046/j.1365-2133.2002.48452.x Mrowietz, 2000, Treatment of severe psoriasis with anti-CD25 monoclonal antibodies, Arch Dermatol, 136, 675, 10.1001/archderm.136.5.675 Salim, 2000, Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker), Br J Dermatol, 143, 1121, 10.1046/j.1365-2133.2000.03878.x Rebora, 2002, Basiliximab is effective for erosive lichen planus, Arch Dermatol, 138, 1100, 10.1001/archderm.138.8.1100 Guhl, 2006, [Epidermal growth factor receptor inhibitors side effects], Actas Dermosifiliogr, 97, 296, 10.1016/S0001-7310(06)73407-X http://emea.europa.eu/humandocs/Humans/EPAR/erbi-tux/erbitux.htm. Consultado 30 junio 2007. http://emea.europa.eu/humandocs/PDFs/EPAR/erbitux/H-558-PI-es.pdf. Consultado 30 junio 2007. Suen, 2007, Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab, Anticancer Drugs, 18, 827, 10.1097/CAD.0b013e32809ef9e0 Bauman, 2007, Treatment of recurrent squamous cell carcinoma of the skin with cetuximab, Arch Dermatol, 1, 889 http://clinicaltrials.gov/ct/show/NCT00240682? Consultado 30 julio 2007. Ben-Bassat, 2001, Biological activity of tyrosine kinase inhibitors: novel agents for psoriasis therapy, Curr Opin Investig Drugs, 2, 1539 Mueller, 2006, Basal-cell carcinoma, N Engl J Med, 354, 769, 10.1056/NEJMc053488